TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18289809

Group type: EXPERIMENTAL
Intervention: Tempo inhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercial inhaler
Number of subjects: 12
Study: 15919846

Group type: EXPERIMENTAL
Intervention: TM-CD care (n = 329) including AUC elements plus 'stage of change' assessments, mailed workbooks, and monthly calls
Number of subjects: 665

Group type: COMPARATOR
Intervention: Augmented usual care (AUC) (n = 336) including dietary and exercise advice, prescriptions, and dietary recalls
Number of subjects: 665
Study: 12771562

Group type: EXPERIMENTAL
Intervention: Ethanol intake
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Saturated and polyunsaturated lipids intake
Number of subjects: 620

Group type: COMPARATOR
Intervention: Protein and carbohydrate intake
Number of subjects: 620

Group type: COMPARATOR
Intervention: Tobacco smoking, body mass index, and regular physical activity
Number of subjects: 620

Group type: COMPARATOR
Intervention: Height
Number of subjects: 620

Group type: COMPARATOR
Intervention: Age
Number of subjects: 620
Study: 15016225

Group type: EXPERIMENTAL
Intervention: Novo 27G/13 mm (N27)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: B-D MicroFine IV 28G/13 mm (B28)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NovoFine 28G/12 mm (N28)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: B-D MicroFine+ 29G/13 mm (B29)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NovoFine 30G/8 mm (N30)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection (no needle mounted)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All needles
Number of subjects: 100
Study: 8970468

Group type: EXPERIMENTAL
Intervention: ZDV plus didanosine (ddI)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: ZDV plus zalcitabine (ddC)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Randomized arm (ZDV/ddI or ZDV/ddC)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Open arm (ZDV/ddI or ZDV/ddC)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Open arm
Number of subjects: 582

Group type: COMPARATOR
Intervention: Randomized arm
Number of subjects: 582
Study: 1633124

Group type: EXPERIMENTAL
Intervention: Chamomile oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6542835

Group type: EXPERIMENTAL
Intervention: Glucose infusion (4.0 mmol h‐1 kg‐1 b. wht.)
Number of subjects: 6
Study: 31143996

Group type: EXPERIMENTAL
Intervention: Internal Jugular Vein (IJV) catheterization
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Subclavian Vein (SCV) catheterization
Number of subjects: 1484
Study: 28249094

Group type: COMPARATOR
Intervention: Conventional primary PCI (including stent implantation)
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Postconditioning (4 repeated 30-second balloon occlusions followed by 30 seconds of reperfusion)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 1234
Study: 25496674

Group type: EXPERIMENTAL
Intervention: Topical lignocaine (7 puffs of 10% aerosol)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (1.5 mg/kg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Physiological saline (5 ml of 0.9% saline)
Number of subjects: 99
Study: 23583022

Group type: EXPERIMENTAL
Intervention: Aphasia group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 21451755

Group type: EXPERIMENTAL
Intervention: Simulation-based educational experience
Number of subjects: 82
Study: 19373224

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high fat (LC) diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional high carbohydrate, low fat (HC) diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 60
Study: 16439498

Group type: EXPERIMENTAL
Intervention: Pedometer and coaching
Number of subjects: 57

Group type: COMPARATOR
Intervention: Coaching-only
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups (pedometer and coaching, coaching-only)
Number of subjects: 57
Study: 11865969

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (110, 220, 330, or 440 microg bid)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Flunisolide (500 microg or 1000 microg bid)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Salivary cortisol measurement
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control regimens (prednisone or placebo)
Number of subjects: 153
Study: 10036950

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid + Amoxicillin 500 mg qid + Clarithromycin 400 mg bid (OAC)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid + Clarithromycin 400 mg bid (OC)
Number of subjects: 234
Study: 8819747

Group type: EXPERIMENTAL
Intervention: Low structured sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High structured sequence
Number of subjects: 0
Study: 2183719

Group type: EXPERIMENTAL
Intervention: Cefixime (800 mg oral dose)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Amoxicillin (3 g) plus Probenecid (1 g)
Number of subjects: 143
Study: 7401203

Group type: EXPERIMENTAL
Intervention: Washed red cell concentrates
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unwashed red cell concentrates
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups (washed and unwashed)
Number of subjects: 2
Study: 6601746

Group type: EXPERIMENTAL
Intervention: 0.5 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no lidoflazine)
Number of subjects: 0
Study: 30465720

Group type: EXPERIMENTAL
Intervention: Patient Generated Index (PGI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fibromyalgia criteria (2016 modified criteria)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome criteria (Canada criteria)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bodily Distress Syndrome (multi-organ type)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fibromyalgia criteria (2011 and 2010 criteria)
Number of subjects: 33
Study: 29396758

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 12
Study: 27310976

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 25
Study: 24661681

Group type: EXPERIMENTAL
Intervention: Lokomat training (12 sessions of 1 hour each over one month)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 40
Study: 22055480

Group type: EXPERIMENTAL
Intervention: Daily multivitamin‐mineral supplement
Number of subjects: 58
Study: 20458640

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene (HXLP)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 122
Study: 18096536

Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) as second reader
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (without CAD)
Number of subjects: 60
Study: 15921804

Group type: EXPERIMENTAL
Intervention: Echo-Doppler
Number of subjects: 366

Group type: COMPARATOR
Intervention: Therapeutic decision-making based on echo-Doppler findings
Number of subjects: 366
Study: 12051127

Group type: EXPERIMENTAL
Intervention: All-ceramic 3-unit bridges
Number of subjects: 48

Group type: COMPARATOR
Intervention: Porcelain-fused-to-metal bridges
Number of subjects: 48
Study: 10340839

Group type: EXPERIMENTAL
Intervention: Treatment for isolated systolic hypertension; specific intervention details not provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure control in patients with diastolic hypertension; specific intervention details not provided.
Number of subjects: 0
Study: 11324827

Group type: EXPERIMENTAL
Intervention: reverse transcriptase inhibitors (zidovudine or didanosine monotherapy or alternating zidovudine and didanosine)
Number of subjects: 47
Study: 1917502

Group type: EXPERIMENTAL
Intervention: Neighborhood team model
Number of subjects: 0
Study: 7153153

Group type: EXPERIMENTAL
Intervention: Atropine 0.25 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine 1.0 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine 3.0 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine 6.0 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 7
Study: 31927325

Group type: EXPERIMENTAL
Intervention: Higher BP level
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Higher BP variability
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Greater diastolic BP variability
Number of subjects: 961
Study: 30238444

Group type: EXPERIMENTAL
Intervention: Early endovenous ablation of superficial venous reflux within 2 weeks after randomization
Number of subjects: 450

Group type: COMPARATOR
Intervention: Deferred endovenous ablation of superficial venous reflux, with compression therapy alone
Number of subjects: 450
Study: 30132361

Group type: EXPERIMENTAL
Intervention: Triggered monitoring visits
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untriggered monitoring visits
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Triggered monitoring visits (excluding re-consent findings)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untriggered monitoring visits (excluding re-consent findings)
Number of subjects: 42
Study: 26800087

Group type: EXPERIMENTAL
Intervention: Lateral wedge
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lateral wedge plus arch support
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no orthotic)
Number of subjects: 26
Study: 24503784

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily for ≈4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (oral hypoglycemic agents)
Number of subjects: 19
Study: 24837018

Group type: EXPERIMENTAL
Intervention: Accuracy motivation (incentive) with 95% anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accuracy motivation (incentive) with 55% anchor
Number of subjects: 0

Group type: COMPARATOR
Intervention: No accuracy motivation with 95% anchor
Number of subjects: 0

Group type: COMPARATOR
Intervention: No accuracy motivation with 55% anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accuracy motivation (no incentive) with 95% anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accuracy motivation (no incentive) with 55% anchor
Number of subjects: 0
Study: 20703162

Group type: EXPERIMENTAL
Intervention: ER + PC mode
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional PC mode
Number of subjects: 21
Study: 17575561

Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol Contramid OAD tablet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 200 mg Tramadol Contramid OAD tablet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 300 mg Tramadol Contramid OAD tablet
Number of subjects: 27
Study: 15694088

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular 15‐methyl‐prostaglandin F2alpha (125 microg)
Number of subjects: 60
Study: 11866001

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study: 10532693

Group type: EXPERIMENTAL
Intervention: Aggressive treatment with high doses of lovastatin (40-80 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate treatment with low doses of lovastatin (2.5-5 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose warfarin
Number of subjects: 0
Study: 7766739

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 4 weeks
Number of subjects: 219

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4 weeks
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg after 8 weeks
Number of subjects: 219

Group type: COMPARATOR
Intervention: Omeprazole 20 mg after 8 weeks
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg after 2 weeks for patients with ulcer pain
Number of subjects: 219

Group type: COMPARATOR
Intervention: Omeprazole 20 mg after 2 weeks for patients with ulcer pain
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg after 4 weeks for patients with ulcer pain
Number of subjects: 219

Group type: COMPARATOR
Intervention: Omeprazole 20 mg after 4 weeks for patients with ulcer pain
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 219
Study: 2308462

Group type: EXPERIMENTAL
Intervention: 1 mW helium neon continuous-wave (0.633 microns) laser irradiation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 6998274

Group type: EXPERIMENTAL
Intervention: Sucrose diet (30% of calories as sucrose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Starch diet (30% of calories as wheat starch)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sucrose diet after 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Starch diet after 6 weeks
Number of subjects: 19
Study: 31996174

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-intervention support group (Control)
Number of subjects: 126
Study: 31289056

Group type: EXPERIMENTAL
Intervention: Positive Adjustment Coping Intervention (PACI) - daily text messages with positive-adjustment coping attitudes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive distractions - daily text messages with cognitive distractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PACI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive distractions
Number of subjects: 0
Study: 27003945

Group type: COMPARATOR
Intervention: EDSS-Plus
Number of subjects: 215

Group type: COMPARATOR
Intervention: EDSS
Number of subjects: 215

Group type: COMPARATOR
Intervention: T25FW
Number of subjects: 215

Group type: COMPARATOR
Intervention: 9HPT (either hand)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 9HPT (dominant hand)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 9HPT (non-dominant hand)
Number of subjects: 215
Study: 24750784

Group type: EXPERIMENTAL
Intervention: Conventional resistance training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 23149383

Group type: EXPERIMENTAL
Intervention: Volitional pursed lips breathing (PLB) during 6-minute walk test (6MWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volitional pursed lips breathing (PLB)
Number of subjects: 0
Study: 22218098

Group type: EXPERIMENTAL
Intervention: Active blood pressure lowering treatment (indapamide SR 1.5 mg plus perindopril 2-4 mg if required)
Number of subjects: 1712
Study: 19501764

Group type: EXPERIMENTAL
Intervention: Breakfast cereals (specific types not mentioned)
Number of subjects: 0
Study: 16869334

Group type: EXPERIMENTAL
Intervention: Serial Trial Intervention (STI)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nurses using STI
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pharmacological comfort treatments
Number of subjects: 114

Group type: COMPARATOR
Intervention: Nonpharmacological comfort treatments
Number of subjects: 114
Study: 14516240

Group type: EXPERIMENTAL
Intervention: Individual plus group counseling for cocaine dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study: 10636264

Group type: EXPERIMENTAL
Intervention: Dipyridamole (15 mg in 30 min, stopped 5 min before testing)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8811376

Group type: EXPERIMENTAL
Intervention: Early oral intake (Group I) allowed ab libitum intake of clear liquids starting the first evening after the operation, progressing to a regular diet on the first postoperative day.
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Early oral intake (Group I)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (Group II) with nasogastric tube removed when postoperative ileus resolved.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (Group II)
Number of subjects: 190
Study: 1389851

Group type: EXPERIMENTAL
Intervention: Metoclopramide (n = 85)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Lignocaine (n = 85)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (Saline) (n = 85)
Number of subjects: 255
Study: 2865518

Group type: EXPERIMENTAL
Intervention: Combination of mefloquine and sulfadoxine/pyrimethamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sulfadoxine/pyrimethamine
Number of subjects: 36
Study: 29859849

Group type: EXPERIMENTAL
Intervention: D-amp 10mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: D-amp 20mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: D-amp 0.3 mg/kg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 95
Study: 27572344

Group type: EXPERIMENTAL
Intervention: Mirror therapy (15 sessions, daily 30 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional occupational therapy (same amount as experimental group)
Number of subjects: 22
Study: 26112041

Group type: EXPERIMENTAL
Intervention: BALANCE intervention
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1325
Study: 23011680

Group type: EXPERIMENTAL
Intervention: 10 mg prednisone daily with methotrexate-based tight control strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with methotrexate-based tight control strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (prednisone and placebo)
Number of subjects: 0
Study: 22083987

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 81
Study: 18925394

Group type: EXPERIMENTAL
Intervention: Four hour clamping drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional suction drainage
Number of subjects: 60
Study: 16365721

Group type: EXPERIMENTAL
Intervention: Oily calcium hydroxide suspension (OCHS) with access flap surgery (AFS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Access flap surgery (AFS) alone
Number of subjects: 30
Study: 14628976

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Lithium (0.8-1.1 mEq/L)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 966
Study: 11134101

Group type: EXPERIMENTAL
Intervention: OGTT+F (75 g glucose + 7.5 g fructose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: OGTT‐F (75 g glucose without fructose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OGTT+F
Number of subjects: 11

Group type: COMPARATOR
Intervention: OGTT‐F
Number of subjects: 11
Study: 9075447

Group type: EXPERIMENTAL
Intervention: Nurse counseling intervention using the Eating Pattern Assessment Tool and brand-specific food advice; up to 5 counseling visits in the initial study.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nurse counseling intervention (same as above); patients attending 2 or more counseling sessions matched with other patients.
Number of subjects: 135
Study: 8277075

Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus N-acetylcysteine (0.1 microgram/kg per min + 2 g intravenously, followed by 5 mg/kg per h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitroglycerin plus placebo (0.1 microgram/kg per min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus N-acetylcysteine
Number of subjects: 8
Study: 2929629

Group type: EXPERIMENTAL
Intervention: 150 mg PPA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 mg PPA plus 400 mg caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 mg PPA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29703040

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at ST36-ST37, 20 minutes twice a day for 5 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional therapies (control group)
Number of subjects: 82
Study: 28396238

Group type: EXPERIMENTAL
Intervention: Low dose low molecular weight heparin (LMWH) combined with graduated compression stockings (GCS)
Number of subjects: 2236

Group type: COMPARATOR
Intervention: Low dose low molecular weight heparin (LMWH) alone
Number of subjects: 2236
Study: 25975523

Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy
Number of subjects: 553

Group type: COMPARATOR
Intervention: 3D microscopy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy (infiltrative/sclerosing/morpheaform tumors)
Number of subjects: 553

Group type: COMPARATOR
Intervention: 3D microscopy (infiltrative/sclerosing/morpheaform tumors)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Breadloaf microscopy (solid/nodular tumors)
Number of subjects: 553

Group type: COMPARATOR
Intervention: 3D microscopy (solid/nodular tumors)
Number of subjects: 553
Study: 24524874

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no physical therapy)
Number of subjects: 43
Study: 22033572

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (Beconase(®)), 200 μg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (FESS(®) saline nasal spray)
Number of subjects: 19
Study: 20109208

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg for 4 weeks followed by 10 microg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 54
Study: 18724191

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interview (ACASI) system
Number of subjects: 0